

An Economic Evaluation of Physical Activity and Implications for Its Promotion



Aliza Matusevich¹, Prof. Moshe Leshno³, Prof. Amir Shmueli¹, Prof. Mayer Brezis²

Braun School of Public Health, Hadassah-Hebrew University Jerusalem¹,
Center for Clinical Quality & Safety, Hadassah-Hebrew University Medical Center²,
Faculty of Management and Sackler Faculty of Medicine, Tel-Aviv University³



Introduction
Physical activity (PA) is known to positively influence morbidity and mortality from many common chronic conditions. While the health benefits of physical activity are well documented the economic benefits are less clear.

Objective
Limited research published to date has calculated the benefits of PA in terms of costs, quality of life and life expectancy resulting from those conditions responsible for the majority of morbidity and mortality in the Western world. This paper aims to calculate the savings engendered when a sedentary person becomes active and, to extrapolate those findings to a population level by means of a comparison between the cost-effectiveness of enabling physical activity and a laissez-faire stance.

Method
The study builds two decision-analysis models for a cohort of healthy 40-year-olds using a decision tree: A cost minimization (CMA) and a cost-utility analysis (CUA). Both include data collected from local and international literature on disease costs, utilities and lifetime risks and physical activity's impact on these factors.


Results
The CMA shows that one can expect a physically active adult to incur \$117,000 less in disease-related costs compared to a sedentary individual. Even if only 1% of the Israeli population becomes active one could invest \$90 million a year and still realize a saving.
The CUA then calculates at what levels of population adherence to PA recommendations and at what level of societal investment enabling PA would be cost-effective.
In the base case, assuming a \$10,000 per person lifetime investment and a 25% increase in proportion of active individuals, the mean incremental cost-effectiveness ratio (ICER) of promoting PA is under \$600 per QALY gained.
In univariate sensitivity analysis, the most important variables are the effectiveness and cost of the intervention as well as the percentage of the population currently active. The model is less sensitive to the degree to which PA decreases disease risk and cost and increases utility.

Level & strength of evidence for a relationship between physical activity and contemporary chronic conditions

Condition	Lifetime risk	Lifetime cost	Prevalence	Health-related quality of life	Level of evidence
Cardiovascular disease	High	High	High	High	High
Hypertension	High	High	High	High	High
Diabetes	High	High	High	High	High
Obesity	High	High	High	High	High
Chronic obstructive pulmonary disease	High	High	High	High	High
Depression	High	High	High	High	High
Alcohol use disorders	High	High	High	High	High
Substance use disorders	High	High	High	High	High
Chronic kidney disease	High	High	High	High	High
Chronic liver disease	High	High	High	High	High
Chronic pain	High	High	High	High	High
Chronic respiratory disease	High	High	High	High	High
Chronic mental health conditions	High	High	High	High	High
Chronic infectious diseases	High	High	High	High	High
Chronic neurological conditions	High	High	High	High	High
Chronic musculoskeletal conditions	High	High	High	High	High
Chronic autoimmune conditions	High	High	High	High	High
Chronic skin conditions	High	High	High	High	High
Chronic eye conditions	High	High	High	High	High
Chronic hearing and vision conditions	High	High	High	High	High
Chronic dental conditions	High	High	High	High	High
Chronic oral conditions	High	High	High	High	High

One-way Sensitivity Analysis


Disease risk reduction and incremental cost savings



If disease risk is reduced by 60% a sedentary individual who becomes active can expect to incur \$200,000 less in medical costs, Even a 1% decrease in lifetime risk will involve a substantial saving i.e. \$60,000 over a lifetime.




Disease cost reduction and incremental cost savings



Varying disease cost reduction from 1-50% for active people results in a lifetime saving of \$61,000 – 175,000.



Should We Invest in Promoting PA?




CUA base case, two-dimensional (sampling and trials): 50,000 iterations


Statistic	Cost(E)	QALY(E)	Cost(LF)	QALY(LF)	ICER
Mean	\$302,217	23.22	\$302,017	22.87	\$571.43
Minimum	\$86,484	16.84	\$85,507	16.73	\$8,881.82
Median	\$300,671	23.21	\$300,737	22.86	DOMINANT
Maximum	\$570,102	30	\$566,434	28.88	\$3,275.00

ICER = Incremental Cost-Effectiveness ratio
 COST_{new strategy} - COST_{current practice}
 EFFECT_{new strategy} - EFFECT_{current practice}

Net Monetary Benefit (wtp=50000.): Sensitivity Analysis on cE and p_down



Net Monetary Benefit (wtp=50000.): Sensitivity Analysis on cE and Enabling Effect



- Conditions included in the decision tree are:
- Coronary Heart Disease
 - Cerebrovascular Attacks
 - Type 2 Diabetes Mellitus
 - Colon Cancer
 - Breast cancer (for women)
 - Dementia
 - Musculoskeletal disorders (arthritis and hip fracture)




Tree model describing cost-minimization analysis:

P_{down}: reduction in disease risk due to PA
 C_{down}: reduction in disease cost due to PA
 QALY: Quality adjusted life-year (quality of life scale 0-1) * years lived

CMA Base case, Two-dimensional (Sampling and Trials): 50,000 iterations

Statistic	C[PA]	C[no_PA]	Saving
Mean	\$208,219	\$326,260	\$117,041
Minimum	\$47,777	\$104,130	\$56,353
Median	\$204,006	\$323,144	\$119,138
Maximum	\$459,685	\$606,655	\$147,010



Conclusions

If all Israeli 40-year-olds met recommended levels this would translate to a \$9.5 billion saving over the lifetime of the cohort. Thus, the study adds to the growing literature giving weight to arguments that will convince policy-makers that investing in a national programme to promote physical activity is a worthwhile use of public funds.

